****Published September 2018***
MarketVIEW: E.coli (ExPEC) vaccines (CAT: VAMV064)

Product Name	:	**MarketVIEW:** E.coli (ExPEC) vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf, 120 slides) and MS-Excel forecast model (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	September 2018
Catalogue No	:	VAMV064

Background

Extra intestinal pathogenic *E.coli* (ExPEC) is a member of the *Enterobacteriaceae* bacterial family. It is a leading cause of healthcare-associated (HAI) infections such as bacteremia, urinary tract infections, neonatal sepsis and meningitis. For bacteremias, based on a principal diagnosis from US hospital discharge data, there were 96,560 *E. coli* bacteremias in 2013 compared to 46,140 in 2000, an increase of 109%[1] Although the number *Streptococcal*, *Staphylococcal* and *Pneumococcal* bacteremias also increased over the same time period, in 2009, *E. coli* overtook Staphylococcus as the **leading cause** of bacteremia. Importantly, carbapenem-resistant *E. coil* is also considered an "urgent" threat according to the US CDC. *E.coli* is also a common cause of community-acquired, uncomplicated UTIs, which are a common cause of US emergency department and primary care visits. According to NHANES III, around 12% of women reported a UTI in the last 12 months.

Currently, there is no vaccine to prevent ExPEC infections. Janssen Pharmaceuticals is co-developing **JNJ-63871860 or 860/ExPEC-4V**, a 4-valent "O" antigen conjugate vaccine (the O antigen forms part of the E. coli lipopolysaccharide), currently in Phase II development. The company have reported promising safety and immunogenicity data that warrants further investigation. Other approaches such as subunit or whole vaccines have been under investigation but are not currently in active development.

The **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of ExPEC vaccines across major Western markets to 2035. Indications considered are the prevention of invasive ExPEC disease in >18 yrs (risk and non-risk) and prevention of recurrent UTIs in females 18-64 yrs. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates based on recently released analyses. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted by a potential vaccine.

---

[1] Van der Mee-Marquet NL et al. Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly.

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to *E.coli* (extra intestinal pathogenic, ExPEC) and related pathogens e.g. hospital associated infections. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel bacterial and nosocomial vaccines has also been utilised.

PRODUCT CONTENTS:
Published September 2018 (CAT No: VAMV064)

****This product is composed of a forecast model (.xls) and a summary presentation (.pdf)

Contents – Summary presentation (.pdf)[2]

Contents
Author's notes
Executive summary
[SECTION 1] ExPEC vaccines - Commercial model: key outputs
[SECTION 2] ExPEC infections - Disease background, epidemiology and impact
[SECTION 3] ExPEC infections - Current treatment and management
[SECTION 4] ExPEC infections - Antibiotic resistance trends
[SECTION 5] ExPEC vaccines - History, current R&D pipeline
[SECTION 6] ExPEC vaccines - Modelling commercial potential, assumptions & methodology
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~120 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >50 interconnected

---

[2] Full contents i.e. title per slide is available upon request

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail:** info@vaczine-analytics.com

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o FULL PRODUCT - USD **$8995.00**/ GBP **£7025.00**[#] (Region license)*

[#] Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.


VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the **"spiral logo"** are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail: info@vaczine-analytics.com**

BIBLIOGRAPHY

References – available upon request

.

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).

2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.

3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.

4. If not purchased on line invoices are payable within **thirty days** of the invoice date.

5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.

6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   **Tel.** +44(0)1279 927049   **e-mail: info@vaczine-analytics.com**